A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Cancer

Protocol
10-226
Full Title
A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Phase
II
Purpose

Everolimus and bevacizumab are two drugs already approved for treating advanced renal cell carcinoma, a serious form of kidney cancer. In this study, researchers are evaluating the safety and effectiveness of using both drugs together in patients with advanced non-clear cell renal cell cancer. The hope is that both drugs together may be more effective than either drug alone.

Everolimus is an oral drug that inhibits a molecule called mTOR, which helps cancer cells grow. Bevacizumab inhibits the formation of blood vessels that tumors need to grow and spread. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced non-clear cell renal cell cancer.
  • Patients may not have previously received sunitinib, sorafenib, bevacizumab, sirolimus, temsirolimus, everolimus, or deforolimus.
  • At least 4 weeks must have passed since any major surgery or radiation therapy and entry into the study.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Ana M. Molina at 646-422-4313.

Disease(s)
Locations
Related Diseases